Please assess the completion status of the following clinical trial:

Trial Title: Thyroid Hormone Analog Therapy in MCT8 Deficiency: Triac Trial Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* clinically relevant mutation in the MCT8 gene, resulting in the clinical phenotype of AHDS.~Exclusion Criteria:~* Major illness or recent major surgery (within 4 weeks) unrelated to AHDS~* Patients who are participating in ongoing RCTs of therapeutic interventions (including clinical trials of investigational medicinal products);~* Known allergy to components in Triac tablets;~* Patients that have any contra-indication for Triac treatment.

- Gender: MALE
- Minimum Age: 1 Day
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- AHDS patients (Type: EXPERIMENTAL): all AHDS recruited for this study will be located in the experimental arm and will receive the investigational medicinal product Triac. The Triac dose will be individually titrated to the optimal dose level.

Based on this trial design, predict the completion outcome and termination type (if applicable).